UBS Knock-Out AMGN/ DE000UL7AJU4 /
2024-08-30 11:41:17 AM | Chg.+0.020 | Bid11:41:17 AM | Ask11:41:17 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.710EUR | +2.90% | 0.710 Bid Size: 25,000 |
0.730 Ask Size: 25,000 |
Amgen Inc | 255.5851 USD | 2078-12-31 | Call |
GlobeNewswire
08-15
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
08-12
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08-08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-08
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
08-05
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
08-01
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
07-22
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
07-02
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...
GlobeNewswire
06-27
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...
GlobeNewswire
06-27
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All ...
GlobeNewswire
06-25
Arthritis Foundation Launches Carolina Hills Classic Bike Tour, Coming June 2025
GlobeNewswire
06-20
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7...